Vaccinex, Inc.

FOR IMMEDIATE RELEASE

VACCINEX RECEIVES NEW YORK STATE GRANT TO TRAIN HIGH-TECH WORKERS

Rochester, N.Y. June 28, 2001 Vaccinex, Inc. has been awarded a grant from New York State through a funding mechanism designed to retain bachelor's and master's level laboratory technicians in the state following completion of their education. Vaccinex plans to use the funding for on-the-job training for 12 technicians as part of a dramatic expansion of the company's scientific work force.

President and Chief Executive Officer, Maurice Zauderer, said, "We are very grateful to have been selected as a recipient of this grant. Governor Pataki and the state government are committed to retaining graduates of biotechnology and scientific degree programs locally and we will do our part to provide stimulating and rewarding work in a high-tech environment."

Vaccinex was founded in 1997 by Dr. Zauderer, then Professor of Oncology at the University of Rochester, and Deepak Sahasrabudhe, M.D., Director of the Genito/Urinary Oncology Clinic at the University of Rochester Cancer Center. The Vaccinex discovery platform provides a uniquely efficient means of identifying immune target molecules, called antigens, that are recognized by T cells and B cells. By incorporating such antigens into a novel and effective vaccine delivery system the company expects to develop and commercialize vaccines to stimulate the immune system to attack and eradicate tumor cells that express these antigens on their surface. Since 1997, the company has grown to employ 24 scientists and support staff and, in anticipation of continuing growth, has initiated planning for new facilities in Rochester. This New York State award supplements grants received from federal agencies, including an ATP Award from the Department of Commerce, Small Business Innovation Research (SBIR) Grants from the National Cancer Institute of the National Institutes of Health, and the U.S. Army Breast Cancer Research Program.

Back to News Archive


About Us Executive Team Board of Directors Scientific/ Clinical Advisors Business Strategy Collabora- tions Antibody Technology Overview Membrane Antibody Expression and Selection Secreted IgG Antibody Selection Antibody Animation Development Strategy Development Pipeline


	FOR IMMEDIATE RELEASE VACCINEX RECEIVES NEW YORK STATE GRANT TO TRAIN HIGH-TECH WORKERS Rochester, N.Y. June 28, 2001 Vaccinex, Inc. has been awarded a grant from New York State through a funding mechanism designed to retain bachelor's and master's level laboratory technicians in the state following completion of their education. Vaccinex plans to use the funding for on-the-job training for 12 technicians as part of a dramatic expansion of the company's scientific work force. President and Chief Executive Officer, Maurice Zauderer, said, "We are very grateful to have been selected as a recipient of this grant. Governor Pataki and the state government are committed to retaining graduates of biotechnology and scientific degree programs locally and we will do our part to provide stimulating and rewarding work in a high-tech environment." Vaccinex was founded in 1997 by Dr. Zauderer, then Professor of Oncology at the University of Rochester, and Deepak Sahasrabudhe, M.D., Director of the Genito/Urinary Oncology Clinic at the University of Rochester Cancer Center. The Vaccinex discovery platform provides a uniquely efficient means of identifying immune target molecules, called antigens, that are recognized by T cells and B cells. By incorporating such antigens into a novel and effective vaccine delivery system the company expects to develop and commercialize vaccines to stimulate the immune system to attack and eradicate tumor cells that express these antigens on their surface. Since 1997, the company has grown to employ 24 scientists and support staff and, in anticipation of continuing growth, has initiated planning for new facilities in Rochester. This New York State award supplements grants received from federal agencies, including an ATP Award from the Department of Commerce, Small Business Innovation Research (SBIR) Grants from the National Cancer Institute of the National Institutes of Health, and the U.S. Army Breast Cancer Research Program. Back to News Archive Copyright © 2008 Vaccinex, Inc.